Compare DUOT & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DUOT | CGEN |
|---|---|---|
| Founded | 1990 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 210.3M | 220.7M |
| IPO Year | N/A | 2000 |
| Metric | DUOT | CGEN |
|---|---|---|
| Price | $11.23 | $2.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $14.00 | $4.00 |
| AVG Volume (30 Days) | 237.5K | ★ 591.3K |
| Earning Date | 11-12-2025 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,026,308.00 | $6,903,000.00 |
| Revenue This Year | $286.66 | N/A |
| Revenue Next Year | $44.93 | $164.92 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 159.00 | N/A |
| 52 Week Low | $3.84 | $1.13 |
| 52 Week High | $12.17 | $2.66 |
| Indicator | DUOT | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 56.30 | 66.02 |
| Support Level | $10.16 | $2.04 |
| Resistance Level | $11.24 | $2.21 |
| Average True Range (ATR) | 0.68 | 0.15 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 82.61 | 73.64 |
Duos Technologies Group Inc operating under its brand name duostech, designs, develops, deploys and operates intelligent technology solutions supporting rail, logistics and intermodal businesses that streamline operations, improve safety and reduce costs. The company's main offering, the Railcar Inspection Portal (RIP), provides both freight and transit railroad customers and select government agencies the ability to conduct fully automated railcar inspections of trains that are moving at full speed. It has also developed the Automated Logistics Information System (ALIS) which automates gatehouse operations where transport trucks enter and exit large logistics and intermodal facilities. Its segments are Rail, Commercial, Governments, Banking and AI.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.